Ph.D. Daniel Billen - 18 May 2023 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Role
Director
Signature
/s/ Daniel Billen, Ph.D.
Issuer symbol
AUPH
Transactions as of
18 May 2023
Net transactions value
-$52,359
Form type
4
Filing time
23 May 2023, 17:17:48 UTC
Previous filing
20 May 2022
Next filing
22 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AUPH Common Stock Options Exercise +8,733 +44% 28,733 18 May 2023 Direct F1
transaction AUPH Common Stock Award $0 +9,310 +32% $0.000000 38,043 19 May 2023 Direct F2
transaction AUPH Common Stock Sale $52,359 -4,650 -12% $11.26 33,393 23 May 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AUPH Restricted Stock Units Options Exercise $0 -8,733 -100% $0.000000* 0 18 May 2023 Common Stock 8,733 Direct F1
transaction AUPH Stock Option (right to buy) Award $0 +15,234 $0.000000 15,234 19 May 2023 Common Stock 15,234 $10.74 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date.
F2 Represents grant of the RSUs payable solely in common stock of the Issuer. The shares subject to the RSUs shall vest one year from date of grant.
F3 Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs.
F4 The option vests in twelve equal monthly installments commencing on June 19, 2023.